The invention relates to a process for the preparation of the gadolinium dimeric contrast agent [p-[1-[bis[2-(hydroxy-KO)-3-[4,7,10-tris[(carboxy-KO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-K/V1,K/V4,K/V7,K/V10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex. Such process includes preparation steps carried out one-pot and without isolation of the obtained intermediates. The gadolinium dimeric contrast agent can be for use in diagnostic imaging, in particular in Magnetic resonance Imaging (MRI).
The present invention relates to the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a process for the synthesis of lopamidol using a reactive extrusion process in continuous which enable an efficient conversion of the relevant key intermediates, preferably in the absence of any solvent. The invention further relates to the preparation of radiographic X-rays contrast agents or key intermediates thereof by exploiting the technology of reactive extrusion.
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 231/14 - Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
C07C 237/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and at least three atoms of bromine or iodine, bound to carbon atoms of the same non-condensed six-membered aromatic ring
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Image processing software for increasing the image
enhancement in contrast-enhanced images during medical
examinations. Software as a service (SAAS) services featuring image
processing software for increasing the image enhancement in
contrast-enhanced images during medical examinations.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations. (1) Software as a service (SAAS) services featuring image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations.
The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutamic acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic System
6.
TRAINING OF A MACHINE LEARNING MODEL FOR USE IN MEDICAL IMAGING APPLICATIONS BASED ON COMBINATIONS OF INCOMPLETE SAMPLE SETS AND SAMPLE IMAGES SIMULATED THEREFROM
A solution is proposed for training a machine learning model (305) for use in medical imaging applications. A corresponding method (400) comprises providing (403-410) incomplete sample sets for each imaging procedure, each comprising a sample target image (or more) for a sample target-dose of a contrast agent and a sample baseline image (or more). A sample source image (or more) is simulated (411- 445; 450-456) from each of the incomplete sample sets (or a part thereof) to mimic the contrast agent at a sample source-dose lower than the sample target-dose. One or more complete sample sets are generated (446; 457) for each imaging procedure by combining the incomplete sample sets with the sample source images that have been simulated from other incomplete sample sets. The machine learning model (305) is then trained (458-473) using the complete sample sets. In addition, a method of using the machine learning model in a medical imaging application is proposed. A computer programs (300) and a computer program products for implementing the method (400) are proposed. Moreover, a computing system (130) for performing the method (400) is proposed. A corresponding medical method is further proposed.
The invention relates to a process for the manufacturing of a solution of a dimeric C gadolinium complex, such as [μ-[1-[bis[2-(hydroxy-xO)-3-[4,7,10-tris[(carboxy-xO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4, κN7,κN10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]digadoliniumcomplex, which is useful in the field of diagnostic imaging and of contrast agents in Magnetic Resonance Imaging (MRI), comprising the steps of precipitating a portion of free gadolinium metal ions by means of a precipitating agent. The invention further relates to a process for isolating the dimeric gadolinium complex from said solution, and to the solution and the isolated dimeric gadolinium complex obtainable by such processes.
A solution is proposed relating to medical imaging applications. Particularly, a method (600) for imaging a body-part of a patient comprises simulating (624-630) corresponding operative simulation images from an operative baseline image and operative administration images, which operative administration images have been acquired with administration of a contrast agent at an operative administration-dose: the operative simulation images mimic administration of the contrast agent at a higher dose. For this purpose, a machine learning model (420) is used that has been trained to optimize a capability thereof to mimic a corresponding increase of the contrast agent from a sample source-dose to a sample target-dose: the sample source-dose is different from the operative administration-dose. Corresponding computer program (500) and computer program product for implementing the imaging method (600) are proposed. Moreover, a computing system (115) for performing the imaging method (600) and an imaging system (105) comprising the computing system (115) and a scanner (110) are proposed. A medical method based on the same imaging method (600) is further proposed.
A solution is proposed for training a machine learning model (420) for use in medical imaging applications. A corresponding method (700) comprises providing (703-743: 759-763) sample sets, each comprising a sample baseline image, a sample target image (acquired from a corresponding body-part of a subject to which a contrast agent at a certain dose has been administered) and a sample source dose (corresponding to a different dose of the contrast agent). The machine learning model (420) is trained (744-758) so as to optimize its capability of generating each sample target image from the corresponding sample baseline image and sample source image. One or more of the sample sets are incomplete, missing their sample source images. Each incomplete sample set is completed (704-742: 759-763) by simulating the sample source image from at least the sample baseline image and the sample target image of the sample set. A computer programs (500) and a computer program products for implementing the method (700) are proposed. Moreover, a computing system (130) for performing the method (700) is proposed.
The invention is related to a process for preparing a iodinating X-rays contrast agent. More specifically, it relates to a process for the preparation of N,N′-bis-(2,3-dihydroxypropyl)-5-hydroxy-2,4,6-triiodo-1,3-benzenedicarboxaniide (I) by electrochemical iodination of N,N′-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide (II) with molecular iodine (I2) which is in situ electrochemically generated from a source of iodide ions (I−). The iodide ions (I−) are obtained by the dissolution of hydrogen iodide (HI) or an alkali metal iodide in the reaction medium or produced during the reaction of N,N′-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide with I2. The invention also relates to the use of the intermediate compound of formula (I), obtained through the above electrochemical iodination of compound (II), in the preparation of N,N′-bis[2,3-dihydroxypropyl]-5(hydroxyacetyl)methylamino]-2,4,6-triiodo-1,3-benzenedicarboxamide (iomeprol).
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 237/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and at least three atoms of bromine or iodine, bound to carbon atoms of the same non-condensed six-membered aromatic ring
The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-κO)-3-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot (without isolation of the obtained intermediate) and precipitation of at least part of free gadolinium metal ions in excess.
The present invention is related to the synthesis of 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which can be subsequently hydrolyzed to 2-amino-1,3-propanediol (serinol), by reacting glycerol and urea: (I) In general, glycerol is heated with urea and a catalyst, with or without a solvent, to give mainly 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which is hydrolyzed in the next step to 2-amino-1,3-propanediol (serinol). Alternatively, glycerol 1,2-carbonate can be used instead of glycerol. Serinol obtained by the process of the invention may be used in the synthesis of Iopamidol.
The present invention is related to the synthesis of 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which can be subsequently hydrolyzed to 2-amino-1,3-propanediol (serinol), by reacting glycerol and urea: (I) In general, glycerol is heated with urea and a catalyst, with or without a solvent, to give mainly 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which is hydrolyzed in the next step to 2-amino-1,3-propanediol (serinol). Alternatively, glycerol 1,2-carbonate can be used instead of glycerol. Serinol obtained by the process of the invention may be used in the synthesis of Iopamidol.
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07D 263/24 - Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
The present invention relates to a process for the preparation of Cyclen. in its turn widely employed in the manufacturing of a variety of macrocyclic gadolinium complexes for use as MRI contrast agents. The said process comprises an efficient coupling of glyoxal with triethylene tetramine and the subsequent reduction of the obtained intermediate derivative with an aluminium based reducing agent. The process is particularly advantageous for the industrial scale as it avoids the use and/or formation of hazardous compounds and further provides for Cyclen manufacturing in high yields and purity.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations. Software as a service (SAAS) services featuring image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations.
15.
CATHETERIZATION WITH AUTOMATIC INSERTION AND ROTATION OF NEEDLE AND RELEASE OF FUNCTIONAL ELEMENT
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (Italy)
Inventor
Acemoglu, Alperen
Koskinopoulou, Maria
De Mattos, Leonardo Serra
Abstract
A solution is proposed for accessing a target region (103) within a body-part (106) of a patient. A corresponding catheterization device (400;500a;500b) has a support element (142) for a functional element (115;118) being a needle (118) or a catheter (115) mounted thereon. A curved guide (405) arranged on a slide (141) is used to guide the support element (142). An actuator (148) translates the slide (141) for causing the needle (118) to penetrate the body-part (106). A further actuator (410) rotates the support element (142) for reducing an angle between the needle (118) and the body-part (106) in response to a reaching of the target region (103). A still further actuator (154;254) releases the functional element (115;118) from the support element (142) in response to a completion of its rotation. A robotic system (600) comprising the catheterization device (400;500a;500b) is also proposed. Moreover, a corresponding method (900) for controlling the catheterization device (400;500a;500b) is proposed. A computer program and a corresponding computer program product for implementing the method (900) are further proposed. A method for inserting the catheter into the target region is also proposed.
The present invention relates to a method for precipitating the gadolinium complex of formula (I) from a solution comprising such gadolinium complex by means of mixing a first solution comprising the complex with a second solution, as well as to a method for isolating the precipitated gadolinium complex of formula (I) from a mixture comprising the precipitate; the gadolinium complex of formula (I) can be used as a contrast agent for magnetic resonance imaging (MRI).
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic System
The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family with near-infrared emission characterized by improved physico-chemical and biological properties and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
The present invention relates to the field of optical imaging. More particularly, it relates to fluorescent probes targeting carbonic anhydrase nine (CA-IX) comprising near-infrared (NIR) dyes of the cyanine. The invention also relates to the methods for preparing these compounds, to pharmaceutical compositions and kits incorporating them and to methods of use them as optical diagnostic agents in imaging or therapy of diseases such as solid tumors with hypoxic tissues involving cells expressing CA-IX. The compounds have formula (I).
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
The present invention relates to the field of optical imaging. More particularly, it relates to fluorescent probes targeting carbonic anhydrase nine (CA-IX) comprising near-infrared (NIR) dyes of the cyanine. The invention also relates to the methods for preparing these compounds, to pharmaceutical compositions and kits incorporating them and to methods of use them as optical diagnostic agents in imaging or therapy of diseases such as solid tumors with hypoxic tissues involving cells expressing CA-IX.
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE (Italy)
Inventor
Botta, Mauro
Tei, Lorenzo
Carniato, Fabio
Baranyai, Zsolt
Boccalon, Mariangela
Abstract
The invention relates to the novel compounds of formula (I) as well as ions, stereoisomers, tautomers, hydrates, solvates, pharmaceutically acceptable salts thereof, or mixtures of the same. The compounds of formula (I) are ligands that are able to chelate Fe(III) ions, thereby generating Fe(III) complexes, which are particularly suitable in diagnostic imaging, for example as contrast agents for magnetic resonance imaging (MRI), due to their high relaxivity, thermodynamic stability, kinetic inertness and redox stability.
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
The invention relates to a process for preparing Gadoteridol of formula (I). In particular, the process comprises the use of propylene oxide in the alkylation step of the compound of formula (II), wherein propylene oxide is directly reacted with the compound of formula (II) without being isolated, and wherein propylene oxide is obtained on demand by decomposition of propylene carbonate in the presence of an alkaline or alkaline earth metal halide as catalyst.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations. Software as a service (SAAS) services featuring image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations. Software as a service (SAAS) services featuring image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Recorded image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations; downloadable image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations Software as a service (SAAS) services featuring image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Recorded image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations; downloadable image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations Software as a service (SAAS) services featuring image processing software for increasing the image enhancement in contrast-enhanced images during medical examinations
27.
PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVES
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 235/48 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family with near-infrared emission characterized by improved physico-chemical and biological properties and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them. The compounds have formula (I), formula (I), wherein X is direct bond or —O—; Y is a group selected from linear or branched C1-C6 alkyl, C3-C7 cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups; R1 and R2 are each independently a linear or branched C1-C6 alkyl substituted by a group selected from —SO3H, —COOH, —CONH2 and —COO—C1-C6 alkyl; and R3 is hydrogen, —SO3H or a linear or branched C1-C6 alkyl substituted by —COOH or —CONH—Y, wherein Y is a group selected from linear or branched C1-C6 alkyl, C3-C7 cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-kO)-3-[4,7,10-tris[(carboxy-kO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-kN1,kN4,kN7,kN10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot and without isolation of the obtained intermediate.
The present invention provides new polypeptide derivatives binding to Human Epidermal Growth Factor Receptor 2 (HER2) and their conjugates thereof, and to their use as a diagnostic agent, particularly for early detection, patient stratification and treatment monitoring of forms of cancer characterized by over-expression of HER2.
The present invention relates to a novel process for the preparation of 2,4,6-triiodoisophthalic bisamide derivatives, which are useful intermediates in the preparation of non-ionic X-ray contrast agents, starting from the corresponding acyl chloride intermediates which are amidated in a mixture of specific hydrotropic solvents in the presence of a low amount of water. In addition, the invention relates to the use of such hydrotropic solvents in the preparation of said 2,4,6-triiodoisophthalic bisamide intermediates to produce non-ionic X-ray contrast agents.
C07C 237/32 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
The invention relates to a process for the preparation of the gadolinium dimeric contrast agent [p-[l-[bis[2-(hydroxy-KO)-3-[4,7,10-tris[(carboxy-KO)methyl]-l,4,7,10- tetraazacyclododec-l-yl-K/V1,K/V4,K/V7,K/V10]propyl]amino]-l-deoxy-D-glucitolato(6-)]]di- gadolinium complex. Such process includes preparation steps carried out one-pot and without isolation of the obtained intermediates. The gadolinium dimeric contrast agent can be for use in diagnostic imaging, in particular in Magnetic resonance Imaging (MRI).
The present invention relates to a process for the manufacturing of a mixture comprising the intermediate 1-[bis[2-hydroxy-3-[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1-deoxy-D-glucitol. Such intermediate is useful for the synthesis of the dimeric gadolinium complex [μ-[1-[bis[2-(hydroxy-κO)-3-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]digadolinium complex, which can be employed as a contrast agent in the field of diagnostic imaging, and in particular of Magnetic Resonance Imaging (MRI).
A solution is proposed for training a machine learning model (420) for use in medical imaging applications. A corresponding method (700) comprises providing (703-743; 759-763) sample sets, each comprising a sample baseline image, a sample target image (acquired from a corresponding body -part of a subject to which a contrast agent at a certain dose has been administered) and a sample source dose (corresponding to a different dose of the contrast agent). The machine learning model (420) is trained (744-758) so as to optimize its capability of generating each sample target image from the corresponding sample baseline image and sample source image. One or more of the sample sets are incomplete, missing their sample source images. Each incomplete sample set is completed (704-742; 759-763) by simulating the sample source image from at least the sample baseline image and the sample target image of the sample set. A computer programs (500) and a computer program products for implementing the method (700) are proposed. Moreover, a computing system (130) for performing the method (700) is proposed.
A solution is proposed relating to medical imaging applications. Particularly, a method (600) for imaging a body-part of a patient comprises simulating (624-630) corresponding operative simulation images from an operative baseline image and operative administration images, which operative administration images have been acquired with administration of a contrast agent at an operative administration-dose; the operative simulation images mimic administration of the contrast agent at a higher dose. For this purpose, a machine learning model (420) is used that has been trained to optimize a capability thereof to mimic a corresponding increase of the contrast agent from a sample source-dose to a sample target-dose; the sample source-dose is different from the operative administration-dose. Corresponding computer program (500) and computer program product for implementing the imaging method (600) are proposed. Moreover, a computing system (115) for performing the imaging method (600) and an imaging system (105) comprising the computing system (115) and a scanner (110) are proposed. A medical method based on the same imaging method (600) is further proposed.
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
The invention is related to a process for preparing a iodinating X-rays contrast agent. More specifically, it relates to a process for the preparation of N,N'-bis-(2,3-dihydroxypropyl)-5-hydroxy-2,4,6-triiodo-1,3-benzenedicarboxamide (I) by electrochemical iodination of N,N'-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide (II) with molecular iodine (I2) which is in situ electrochemically generated from a source of iodide ions (I-). The iodide ions (I-) are obtained by the dissolution of hydrogen iodide (HI) or an alkali metal iodide in the reaction medium or produced during the reaction of N,N'-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide with I2. The invention also relates to the use of the intermediate compound of formula (I), obtained through the above electrochemical iodination of compound (II), in the preparation of N,N'-bis[2,3-dihydroxypropyl]-5(hydroxyacetyl)methylamino]-2,4,6-triiodo-1,3-benzenedicarboxamide (iomeprol).
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 235/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 235/48 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 237/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and at least three atoms of bromine or iodine, bound to carbon atoms of the same non-condensed six-membered aromatic ring
The present invention relates to an iron complex having the general formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition formulated for oral and/or parenteral administration, preferably intravenous, said pharmaceutical composition preferably being formulated as an aqueous solution comprising said complex or salt. The present invention further relates to said complex or a salt thereof or said pharmaceutical composition for use as a contrast agent for magnetic resonance imaging (MRI), as well as a method and a kit for in situ preparation of said complex or salt and said pharmaceutical composition.
The present invention relates to the calcium complex of (4RS)(4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl oxa-5,8,11-triazatridecan-13-oato(5-))pentahydrogen (BOPTA) in the form of a salt, to the process for its preparation and to a formulation comprising said salt.
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
The present invention provides new polypeptide derivatives binding to Human Epidermal Growth Factor Receptor 2 (HER2) and their conjugates thereof, and to their use as a diagnostic agent, particularly for early detection, patient stratification and treatment monitoring of forms of cancer characterized by over-expression of HER2.
The invention relates to a process for the preparation of dimeric contrast agents foruse in Magnetic resonance Imaging (MRI), in particular [?-[1-[bis[2-(hydroxy-?O)-3-[4,7,10-tris[(carboxy-?O)methyl]-1,4,7,10-tetraazacyclododec-1-yl-?N1,?N4,?N7,?N10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]di-gadolinium complex, whichincludes preparation steps carried out one-pot (without isolation of the obtainedintermediate) and precipitation of at least part of free gadolinium metal ions in excess.
The invention relates to a process for the manufacturing of a solution of a dimeric gadolinium complex, such as [?-[1-[bis[2-(hydroxy-?O)-3-[4,7,10-tris[(carboxy-?O)methyl]-1,4,7,10-tetraazacyclododec-1-yl-?N1,?N4,?N7,?N10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]digadolinium complex, which is useful in the field of diagnostic imaging and of contrast agents in Magnetic Resonance Imaging (MRI), comprising the steps of precipitating a portion of free gadolinium metal ions by means of a precipitating agent. The invention further relates to a process for isolating the dimeric gadolinium complex from said solution, and to the solution and the isolated dimeric gadolinium complex obtainable by such processes.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07F 3/00 - Compounds containing elements of Groups 2 or 12 of the Periodic System
46.
PROCESS FOR THE MANUFACTURING OF A GADOLINIUM COMPLEX SOLUTION
The invention relates to a process for the manufacturing of a solution of a dimeric gadolinium complex, such as [μ-[1-[bis[2-(hydroxy-κO)-3-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]digadolinium complex, which is useful in the field of diagnostic imaging and of contrast agents in Magnetic Resonance Imaging (MRI), comprising the steps of precipitating a portion of free gadolinium metal ions by means of a precipitating agent. The invention further relates to a process for isolating the dimeric gadolinium complex from said solution, and to the solution and the isolated dimeric gadolinium complex obtainable by such processes.
C07F 3/00 - Compounds containing elements of Groups 2 or 12 of the Periodic System
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention relates to a process for the preparation of dimeric contrast agents foruse in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-κO)-3-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]di-gadolinium complex, whichincludes preparation steps carried out one-pot (without isolation of the obtainedintermediate) and precipitation of at least part of free gadolinium metal ions in excess.
The present invention relates to pharmaceutical compositions comprising an gadolinium-complex and a saturated macrocyclic tetraamine that find application in diagnostic imaging as diagnostic agents, in particular as contrast agents having improved tolerability, specifically in Magnetic Resonance Imaging (MRI), and to their preparation.
The present invention provides nucleic acid aptamers binding to the Carbonic Anhydrase IX (CA-IX) enzyme, derivatives and conjugates thereof and their use as diagnostic tools, particularly for the imaging of organs and tissues expressing CA-IX, or as therapeutic agents for prevention or treatment of CA-IX related diseases.
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to a process for the preparation of Cyclen, in its turn widely employed in the manufacturing of a variety of macrocyclic gadolinium complexes for use as MRI contrast agents. The said process comprises an efficient coupling of glyoxal with triethylene tetramine and the subsequent reduction of the obtained intermediate derivative with an aluminium based reducing agent. The process is particularly advantageous for the industrial scale as it avoids the use and/or formation of hazardous compounds and further provides for Cyclen manufacturing in high yields and purity.
The present invention is related to the synthesis of 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which can be subsequently hydrolyzed to 2-amino-1,3-propanediol (serinol), by reacting glycerol and urea: (I) In general, glycerol is heated with urea and a catalyst, with or without a solvent, to give mainly 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which is hydrolyzed in the next step to 2-amino-1,3-propanediol (serinol). Alternatively, glycerol 1,2-carbonate can be used instead of glycerol. Serinol obtained by the process of the invention may be used in the synthesis of Iopamidol.
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07D 263/24 - Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
C07C 215/10 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
C07C 237/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and at least three atoms of bromine or iodine, bound to carbon atoms of the same non-condensed six-membered aromatic ring
The present invention relates to the field of optical imaging More particularly, it relates to compounds of the cyanine family characterized by improved physico-chemical and biological properties and to their conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C09B 23/06 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups three CH groups, e.g. carbocyanines
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
The present invention relates to the field of optical imaging. More particularly, it relates to a class of monoalkylated cyanine dyes with red to near-infrared (650-900 nm) emission characterized by pH responsiveness and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them. The monoalkylated cyanine dyes have general formula (I) wherein R1 and R3 are independently selected from the group consisting of hydrogen, -SO3H, - COOH and -CONH-Y; and R2 and R4 are hydrogen, or both R1 together with R2 and R3 together with R4, respectively and with the atoms to which they are bonded, form two aryl rings, optionally substituted with from 1 to 4 -SO3H groups; R5 is an alkyl optionally substituted by a group selected from -SO3H, - COOH and -CONH2.
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 33/84 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
The invention relates to a process for preparing Gadoteridol of formula (I).In particular, the process comprises the use of propylene oxide in the alkylation step of the compound of formula (II), wherein propylene oxide is directly reacted with the compound of formula (II) without being isolated, and wherein propylene oxide is obtained on demand by decomposition of propylene carbonate in the presence of an alkaline or alkaline earth metal halide as catalyst.
The present invention refers to pharmaceutical compositions comprising a macrocyclic gadolinium complex and a water-soluble polyarylene additive useful in diagnostic imaging as diagnostic agents, in particular as contrast agents, specifically in Magnetic Resonance Imaging (MRI).
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
58.
METHOD FOR LABELING OF SENSITIVE AND THERMOSENSITIVE TARGETING BIOMOLECULES WITH TECHNETIUM BASED COMPOUNDS
The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99mTc(N)(PNP)]-based compound suitable for a kit formulation.
The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [?-[1-[bis[2-(hydroxy-kO)-3- [4,7,10-tris[(carboxy-kO)methyl]-1,4,7,10-tetraazacyclododec-1-yl- kN1,kN4,kN7,kN10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot and without isolation of the obtained intermediate.
The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-kO)-3- [4,7,10-tris[(carboxy-kO)methyl]-1,4,7,10-tetraazacyclododec-1-yl- kN1,kN4,kN7,kN10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot and without isolation of the obtained intermediate.
A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their use as diagnostic or therapeutic agents.
The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family with near- infrared emission characterized by improved physico-chemical and biological properties and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them. The compounds have formula (I), formula (I), wherein X is direct bond or -O-; Y is a group selected from linear or branched C1-C6 alkyl, C3-C7 cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups; R1 and R2 are each independently a linear or branched C1-C6 alkyl substituted by a group selected from -SO3H, -COOH, -CONH2 and - COO-C1-C6 alkyl; and R3 is hydrogen, -SO3H or a linear or branched C1-C6 alkyl substituted by -COOH or -CONH-Y, wherein Y is a group selected from linear or branched C1-C6 alkyl, C3-C7 cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups.
The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family with near- infrared emission characterized by improved physico-chemical and biological properties and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them. The compounds have formula (I), formula (I), wherein X is direct bond or -O-; Y is a group selected from linear or branched C1-C6 alkyl, C3-C7 cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups; R1 and R2 are each independently a linear or branched C1-C6 alkyl substituted by a group selected from -SO3H, -COOH, -CONH2 and - COO-C1-C6 alkyl; and R3 is hydrogen, -SO3H or a linear or branched C1-C6 alkyl substituted by -COOH or -CONH-Y, wherein Y is a group selected from linear or branched C1-C6 alkyl, C3-C7 cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups.
Disclosed are gene signatures and methods for predicting the recurrence of prostate cancer in prostatectomized subjects. Other objectives of the invention are assay devices and kits for determining the expression levels of specific gene sets correlated to prostate cancer recurrence.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
71.
ICAM-1 aptamers, diagnostic and therapeutic uses thereof
The present invention provides nucleic acid aptamers binding to the Intercellular Adhesion Molecule-1 (ICAM-1), derivatives and conjugates thereof and their use as diagnostic tools, particularly for the imaging of organs and tissues expressing ICAM-1, or as therapeutic agents for prevention or treatment of ICAM-1-related diseases.
The present invention relates to on the use of exogenous agents having a pool of mobile proton(s) in CEST-MR imaging to generate Chemical Exchange Rotation Transfer-based CEST contrast, and to a ratiometric-based CEST-MR procedure that comprises using these exogenous agents to set-up CERT-based concentration-independent CEST MR imaging, and as responsive agents to set-up CERT-based concentration independent responsiveness.
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
The present invention relates to an iron complex having the general formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition formulated for oral and/or parenteral administration, preferably intravenous, said pharmaceutical composition preferably being formulated as an aqueous solution comprising said complex or salt. The present invention further relates to said complex or a salt thereof or said pharmaceutical composition for use as a contrast agent for magnetic resonance imaging (MRI), as well as a method and a kit for in situ preparation of said complex or salt and said pharmaceutical composition.
The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
The present invention provides new polypeptide derivatives binding to Human Epidermal Growth Factor Receptor 2 (HER2) and their conjugates thereof, and to their use as a diagnostic agent, particularly for early detection, patient stratification and treatment monitoring of forms of cancer characterized by over-expression of HER2.
The present invention relates to the calcium complex of (4RS)(4-carboxy-5,8,11- tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))pentahydrogen (BOPTA) in the form of a salt, to the process for its preparation and to a formulation comprising said salt.
C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
C07C 229/36 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
77.
ANTI-HER2 POLYPEPTIDES DERIVATIVES AS NEW DIAGNOSTIC MOLECULAR PROBES
The present invention provides new polypeptide derivatives binding to Human Epidermal Growth Factor Receptor 2 (HER2) and their conjugates thereof, and to their use as a diagnostic agent, particularly for early detection, patient stratification and treatment monitoring of forms of cancer characterized by over-expression of HER2.
The present invention provides new polypeptide derivatives binding to Human Epidermal Growth Factor Receptor 2 (HER2) and their conjugates thereof, and to their use as a diagnostic agent, particularly for early detection, patient stratification and treatment monitoring of forms of cancer characterized by over-expression of HER2.
The present invention relates to pharmaceutical compositions comprising an gadolinium-complex and a saturated macrocyclic tetraamine that find application in diagnostic imaging as diagnostic agents, in particular as contrast agents having improved tolerability, specifically in Magnetic Resonance Imaging (MRI), and to their preparation.
The present invention provides nucleic acid aptamers binding to the Carbonic Anhydrase IX (CA-IX) enzyme, derivatives and conjugates thereof and their use as diagnostic tools, particularly for the imaging of organs and tissues expressing CA-IX, or as therapeutic agents for preventionor treatment of CA-IX related diseases.
The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family characterized by improved physico-chemical and biological properties and to their conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them.
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family characterized by improved physico-chemical and biological properties and to their conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 7/52 - Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
The present invention relates to new class of functionalized macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention discloses a solid-phase process for the preparation of a Near Infra-Red (NIR) fluorescent probe characterized by an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions.
The present invention refers to pharmaceutical compositions comprising a macrocyclic gadolinium complex and a water-soluble polyarylene additive useful in diagnostic imaging as diagnostic agents, in particular as contrast agents, specifically in Magnetic Resonance Imaging (MRI).
A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their use as diagnostic or therapeutic agents.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
93.
GENE SIGNATURES FOR THE PREDICTION OF PROSTATE CANCER RECURRENCE
Disclosed are gene signatures and methods for predicting the recurrence of prostate cancer in prostatectomized subjects. Other objectives of the invention are assay devices and kits for determining the expression levels of specific gene sets correlated to prostate cancer recurrence.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
94.
Process for the recovery of iodine from aqueous solutions
The invention relates to a process for the recovery and recycling of the iodine from aqueous solutions comprising iodine-comprising aromatic compounds in which the iodine contained in said aromatic compounds is directly converted into molecular iodine at a pH lower than 1, in the absence of a catalyst.
The present invention generally relates to a process using a mechanochemical approach exploiting the mechanical milling of reactants for the manufacturing of acetyl Iopamidol and, more generally, of key intermediates of radiographic contrast agents, and of the contrast agents themselves.
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
96.
Method for labeling of sensitive and thermosensitive targeting biomolecules with technetium based compounds
The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.
The present invention relates to a process for the preparation of a solid form of the gadobenate dimeglumine compound that comprises obtaining a solution of the said compound in a suitable solvent A wherein the amount by weight of the water optionally present in the solution is at most equal to or lower than the amount by weight of the gadobenate dimeglumine comprised in the solution and adding the obtained solution to an organic solvent B, acting as an appropriate antisolvent and favoring the formation of a solid form of the gadobenate dimeglumine that can be collected by filtration.
A61K 49/18 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
The application relates to a process for the synthesis of a Near Infra-Red (NIR) fluorescent probe which is a cRGD-Cy5.5 conjugate of formula (I) known as DA364 comprising an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions.
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA- tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.
The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutamic acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.
